Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Adaptimmune Therapeutics's revenue for the twelve months ending Jun 30, 2025 was $65.09M, down 54.0% year over year. For fiscal 2024 it was $178.03M, up 195.3% from the year before. The highest annual figure on record is $178.03M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $178.03M | +195.3% |
| FY2023 | Dec 31, 2023 | $60.28M | +122.0% |
| FY2022 | Dec 31, 2022 | $27.15M | +341.5% |
| FY2021 | Dec 31, 2021 | $6.15M | +55.4% |
| FY2020 | Dec 31, 2020 | $3.96M | +252.8% |
| FY2019 | Dec 31, 2019 | $1.12M | -98.1% |
| FY2018 | Dec 31, 2018 | $59.51M | +57.3% |
| FY2017 | Dec 31, 2017 | $37.83M | +283.3% |
| FY2015 | Jun 30, 2015 | $9.87M | +1096.5% |
| FY2014 | Jun 30, 2014 | $825.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $13.68M | -89.3% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $7.29M | +28.3% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $3.22M | +1294.8% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $40.90M | +458.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $128.23M | +2399.6% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $5.68M | -88.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $231.00K | -97.9% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $7.32M | +4.5% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $5.13M | -7.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $47.60M | +1231.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $11.03M | +678.3% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $7.01M | +482.5% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $5.54M | +78.9% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $3.58M | +723.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $1.42M | -5.7% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $1.20M | +0.8% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $3.10M | +516.5% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $434.00K | -43.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $1.50M | +106.3% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $1.19M | +403.4% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $502.00K | +219.7% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $761.00K | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $728.00K | -50.8% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $237.00K | -99.4% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $157.00K | -98.3% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $0 | -100.0% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $1.48M | -65.4% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $40.79M | +50.1% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $9.04M | +156.7% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $8.20M | +186.9% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $4.27M | +53.4% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $27.19M | +896.5% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $3.52M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $2.86M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $2.78M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $2.73M | – |
See a number that looks wrong?